Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The objective is to compare the efficacy and safety of oral masitinib 3, 4,5 mg/kg/day or 4.5 mg/kg/day with a switch after 12 weeks of treatment to 6 mg/kg/day in combination with cholinesterase inhibitors and/or memantine to placebo in combination with cholinesterase inhibitors and/or memantine in patients with mild-to-moderate Alzheimer’s disease. • Primary endpoint: - Effect on self-care and activities of daily living assessed by Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL) at Week 24.
Critère d'inclusion
- mild to moderate Alzheimer's Disease